
    
      A total of 130 patients with steroid-resistant aGVHD after allo-HSCT are enrolled in this
      multicenter, randomized, controlled trial. Patients were randomized to UC-MSC + anti-CD25
      monoclonal antibodies (mAb) group and anti-CD25 mAb group. The complete response (CR) rate
      after 4 weeks of treatment in the two groups will be compared. Adverse events are also
      recorded throughout the study.
    
  